Pfizer Corporation

Pharmacia & Upjohn Company

Nordson Corporation

Pharmacia & Upjohn

Ctxt Pty Limited

Robert Louis Hoffman

Michael D Ennis

Kristine E Frank

Jian-Min Fu

Patrick Robert Verhoest

Sacha Ninkovic

Kevin Daniel Freeman-Cook

Jeffrey W Corbett

Asako Nagata

Robert Steven Kania

Douglas Carl Behenna

Cynthia Louise Palmer

Michael Raymond Collins

Paul Francis Richardson

Scott Channing Sutton

Jingrong Jean Cui

Peter Qinhua Huang

John Charles Kath

Judith Gail Deal

Aaron Craig Burns

Sajiv Krishnan Nair

Pei-Pei Kung

Eugene Yuanjin Rui

Mehran Jalaie

Simon Bailey

Ping Chen

Maria Angelica Linton

Michele Ann McTigue

Daniel Tyler Richter

Ted William Johnson

Phuong Thi Quy Le

Benjamin Joseph Burke

Qinhua Huang

Samantha Elizabeth Greasley

Graham Smith

Lakshmi Sourirajan Narasimhan

Neal William Sach

Martha Alicia Ornelas

Douglas K Hutchinson

Richard Charles Thomas

David John Anderson

Dafydd Rhys Owen

Michelle Ang Camerino

Toni-Jo Poel

Jamison Bryce Tuttle

Matthew Forrest Sammons

Robert Arnold Kumpf

Todd S Weston

Suman Luthra

Samir Kulkarni

Paul Anthony Stupple

Anil Mahadeo Rane

Ylva Elisabet Bergman Bozikis

Klimentina Dimitrova Pencheva

Jacques Mycke

Oleg Brodsky

Jonathan Richard Lillis

Howard Acum

Martyn David Ticehurst

Emma Louise Hawking

Nabil B Ghazal

Rohit Jaini

Padmavani Bezawada

Andrew John Thiel

Bradley Paul Sullivan

Matthew Nathan O'Brien Laramy

Rebecca M Olson

Ylva Elisabet Bozikis

Michele Ann Mctigue

The invention relates to compounds of formula I wherein R, Rand - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

Compounds and methods for the treatment of COVID-19

This invention relates to compounds of Formula (I)

CDK2 inhibitors

This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R, Rand Rare as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

This invention relates to compounds of general Formula (I) 

CDK2/4/6 inhibitors

This invention relates to compounds of Formula (I) 

The present invention relates to compounds of formula (I) 

Cycloalkyl-linked diheterocycle derivatives

The present invention relates to compounds of formula (I)  or pharmaceutically acceptable salts thereof, wherein A, L, D, R-R, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

The invention relates to compounds of formula (&#x3a6;) 

Macrocyclic derivatives for the treatment of diseases

The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRFreceptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRFreceptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRFreceptors.

[object Object]

This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRFreceptors, including human CRFreceptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.

Substituted pyrimidine derivatives

Substituted aryl pyrazine derivatives of the formula I as defined herein,and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

Substituted aryl 1, 4-pyrazine derivatives

An applicator for dispensing a conformal coating material onto a substrate. The applicator has a body with a nozzle having a dispensing orifice at a distal end of the body, and assist air is supplied to a location adjacent the dispensing orifice. A seat is disposed in the nozzle around the dispensing orifice, and an end of a needle is movable into contact with and through the seat to terminate a flow of the coating material through the dispensing orifice and eliminate any coating material flow path downstream of the seat. A needle guide is used to laterally support the needle above the nozzle. The distal end of a nozzle is the distal end of the applicator and is exposed for cleaning.

Conformal coating applicator and method

Growing community of inventors

San Marcos, CA, United States of America

Robert Louis Hoffman